Global Chemosynthetic Polypeptide Drugs Market by Type (Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate), By Application (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Chemosynthetic Polypeptide Drugs Market size is set to reach USD 2.9 billion by 2028, at a CAGR of 5.8%. The growth is attributed to the rising demand for advanced medications and increasing incidence rates of bacterial infections worldwide, coupled with the availability of strong pipeline products which are expected to be approved over the forecast period.
A Chemosynthetic Polypeptide Drug is a type of pharmaceutical that works to slow the progression of chronic conditions and reduce symptoms. Chemosynthetic polypeptides are typically used to treat various forms of cancer, as well as autoimmune disorders such as rheumatoid arthritis or lupus. Chemosynthetic polypeptide drugs are biological medications that are synthetic versions of natural substances produced by living organisms that can be used for therapeutic purposes to mimic the effects of a natural hormone or other protein in the human body.
On the basis of Type, the market is segmented into vasopressin, bacitracin, icatibant, colistin (polymyxin E), and polymyxin B and Colistin Methanesulfonate.
Vasopressin:
Vasopressin is a naturally occurring hormone that regulates the body's water balance. It also increases blood pressure and lowers heart rate by narrowing or tightening blood vessels, especially in skeletal muscles. Vasopressin may be used to treat low-blood volume caused by bleeding, liver disease, kidney disorders, cancer treatment such as chemotherapy, or surgery when other treatments are not effective. The vasopressins segment is further classified into adrenaline-containing ones such as dopamine or dobutamine and non-adrenaline containing ones like oxytocics including terlipressin and isoproterenol.
Bacitracin:
Bacitracin is an antibiotic that belongs to the group of polypeptide antibiotics. It falls under the category of narrow-spectrum agents, which means it only attacks a specific type or range of bacteria. Bacitracin can't attack other types such as Gram-positive and Gram-negative organisms. The drug was first isolated from a strain of Streptomyces griseus in 1948 by Dr. Florence. The drug has been used for decades because it's effective against certain kinds of infections.
Icatibant:
Icatibant is a synthetic peptide designed to mimic the activity of natural endothelin-A receptor antagonists, acting locally on endothelial cells. It acts as an agonist with respect to vasoconstriction and as a potent inhibitor of nitric oxide production by vascular endothelium. Icatibant also causes increased expression of cellular adhesion molecules such as P-selectin and intercellular cell adhesion molecule-I. It has been investigated for use in treating acute atrial fibrillation.
Colistin (polymyxin E):
Colistin is an antibiotic that's used to treat serious bacterial infections. It belongs to a group of antibiotics called polymyxins or colistin, which includes Colistimethate Sodium and Polymyxin B. This drug can be given by mouth in tablet form, intravenously, or through the skin with dressings. Colistin also comes as a powder for injection into a muscle, but this route may only work if kidney function remains intact. The most common side effects are nausea and vomiting, diarrhea, rash, pain at the site where injected.
Polymyxin B:
Polymyxin B is a polypeptide antibiotic that belongs to the group of antibiotics known as colistins. It can be found in some types of bacteriostatic water for injection, but it's also available separately under brand names like Polywax and Fungizone. Its use is limited due to its potential side effects.
Colistin Methane Sulfonate:
Colistin is a last-resort antibiotic used to treat serious infections that do not respond to other treatments. Colistin methanesulfonate has the same mode of action as colistin sulfate, but it can be taken in smaller doses and may have fewer side effects than colistin sulfate.
On the basis of Application, the market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online sales. The respective share of application in the total market is estimated to be 24.0% for hospital pharmacy, 18.0% for retail pharmacy, 34.0% for a drug store, and 30.0% for online sale by 2028.
Hospital Pharmacies:
Hospital pharmacies are used to administer chemotherapeutical drugs in the form of injections, tablets, or liquid. Hospital pharmacies also provide antidotes for drug overdose and poisoning. The use of hospital pharmacy can be seen as a service that both providers to patients with chronic illness and their caregivers As such, they offer advice on medication levels, symptoms management, travel health risks, and general fitness activities like exercise programs which may help people manage their illnesses better. Patients who have undergone chemotherapy will only require medical attention during the period when they are undergoing treatment.
Retail Pharmacies:
Retail pharmacies are used as a distribution channel for chemosynthetic polypeptide drugs to patients in both hospitals and the community. Chemosynthetic polypeptide drugs that retail pharmacists can provide include bacitracin, colistin methanesulfonate, icatibant, leucovorin calcium oral solution, metronidazole injection, and vitamin K prophylaxis.
Drug Stores:
Drug stores are one of the major distribution channels for chemosynthetic polypeptide drugs. Chemists in drugstores dispense and sell medicines to customers. Pharmacists as well play a key role here by providing customized advice on treatment based on individual customer's needs, prescription verification with doctors and other pharmacists, as well as discussing side effects and contraindications related to specific medications or groups of medications that have been prescribed or recommended.
Online Sale:
Online sale is a growing trend in the market and it has been dominating the pharmaceutical industry as well. Online pharmacies are now competing with traditional retail pharmacies through online advertising, promotion of discounts, etcetera which forces retailers to reduce their prices for prescription drugs. The growth of this industry can be attributed to factors such as easy availability of medicines without traveling long distances or waiting in line at local chemists/pharmacies, ability to carry out searches at any time from anywhere across different types of media.
On the basis of Region, the market is segmented into North America, Europe, Asia Pacific, and Latin America. The North American market North America is expected to dominate the market as a result of its high prevalence rates and widespread adoption. It is expected to account for a market share of over 50%. This region also has favorable government reimbursement policies that promote the use of new drugs by patients and healthcare providers. The pharmaceutical industry in this region is booming owing to high investment opportunities.
Europe leads innovation as well as patent filings which have helped it maintain its position despite economic challenges. This region may be affected by Brexit, making trade tariffs more expensive and difficult post-Brexit. As per the Asia Pacific, there are many economies such as China that offer a low-cost manufacturing base with strong growth prospects; hence attracting drug companies from all over the world including Europe and North American regions. Latin America on the other hand possesses significant potential due to the high disease burden, population, and a rapidly increasing middle class.
Up Market Research published a new report titled “Chemosynthetic Polypeptide Drugs Market research report which is segmented by Types (Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate), By Applications (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales), By Players/Companies Peptides International, Biovectra, X-Gen Pharmaceuticals, Eli Lilly, F.Hoffmann-La Roche, Amylin Pharmaceuticals, Novo-Nordisk, Amgen, Ipsen”.
Report Scope
Report Attributes | Report Details |
Report Title | Chemosynthetic Polypeptide Drugs Market Research Report |
By Type | Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate |
By Application | Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales |
By Companies | Peptides International, Biovectra, X-Gen Pharmaceuticals, Eli Lilly, F.Hoffmann-La Roche, Amylin Pharmaceuticals, Novo-Nordisk, Amgen, Ipsen |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 224 |
Number of Tables & Figures | 157 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Chemosynthetic Polypeptide Drugs Market Report Segments:
The market is segmented by Type Vasopressin, Bacitracin, Icatibant, Colistin (Polymyxin E) And Polymyxin B, Colistin Methane Sulfonate and By Application Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales.
Some of the companies that are profiled in this report are:
- Peptides International
- Biovectra
- X-Gen Pharmaceuticals
- Eli Lilly
- F.Hoffmann-La Roche
- Amylin Pharmaceuticals
- Novo-Nordisk
- Amgen
- Ipsen
Chemosynthetic Polypeptide Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Chemosynthetic Polypeptide Drugs Market
Overview of the regional outlook of the Chemosynthetic Polypeptide Drugs Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Chemosynthetic Polypeptide Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Chemosynthetic Polypeptide Drugs Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Vasopressin
2. Bacitracin
3. Icatibant
4. Colistin (Polymyxin E) And Polymyxin B
5. Colistin Methane Sulfonate
7. By Application:1. Hospital Pharmacies
2. Retail Pharmacies
3. Drug Stores
4. Online Sales
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemosynthetic Polypeptide Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Chemosynthetic Polypeptide Drugs Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemosynthetic Polypeptide Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemosynthetic Polypeptide Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemosynthetic Polypeptide Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemosynthetic Polypeptide Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemosynthetic Polypeptide Drugs Market Size & Forecast, 2018-2028
4.5.1 Chemosynthetic Polypeptide Drugs Market Size and Y-o-Y Growth
4.5.2 Chemosynthetic Polypeptide Drugs Market Absolute $ Opportunity
Chapter 5 Global Chemosynthetic Polypeptide Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
5.2.1 Vasopressin
5.2.2 Bacitracin
5.2.3 Icatibant
5.2.4 Colistin (Polymyxin E) And Polymyxin B
5.2.5 Colistin Methane Sulfonate
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Chemosynthetic Polypeptide Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Drug Stores
6.2.4 Online Sales
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemosynthetic Polypeptide Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemosynthetic Polypeptide Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Chemosynthetic Polypeptide Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Chemosynthetic Polypeptide Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
9.6.1 Vasopressin
9.6.2 Bacitracin
9.6.3 Icatibant
9.6.4 Colistin (Polymyxin E) And Polymyxin B
9.6.5 Colistin Methane Sulfonate
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Drug Stores
9.10.4 Online Sales
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Chemosynthetic Polypeptide Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Chemosynthetic Polypeptide Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
10.6.1 Vasopressin
10.6.2 Bacitracin
10.6.3 Icatibant
10.6.4 Colistin (Polymyxin E) And Polymyxin B
10.6.5 Colistin Methane Sulfonate
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Drug Stores
10.10.4 Online Sales
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Chemosynthetic Polypeptide Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Chemosynthetic Polypeptide Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
11.6.1 Vasopressin
11.6.2 Bacitracin
11.6.3 Icatibant
11.6.4 Colistin (Polymyxin E) And Polymyxin B
11.6.5 Colistin Methane Sulfonate
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Drug Stores
11.10.4 Online Sales
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Chemosynthetic Polypeptide Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Chemosynthetic Polypeptide Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
12.6.1 Vasopressin
12.6.2 Bacitracin
12.6.3 Icatibant
12.6.4 Colistin (Polymyxin E) And Polymyxin B
12.6.5 Colistin Methane Sulfonate
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Drug Stores
12.10.4 Online Sales
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Chemosynthetic Polypeptide Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Chemosynthetic Polypeptide Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Chemosynthetic Polypeptide Drugs Market Size Forecast by Type
13.6.1 Vasopressin
13.6.2 Bacitracin
13.6.3 Icatibant
13.6.4 Colistin (Polymyxin E) And Polymyxin B
13.6.5 Colistin Methane Sulfonate
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Chemosynthetic Polypeptide Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Drug Stores
13.10.4 Online Sales
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemosynthetic Polypeptide Drugs Market: Competitive Dashboard
14.2 Global Chemosynthetic Polypeptide Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Peptides International
14.3.2 Biovectra
14.3.3 X-Gen Pharmaceuticals
14.3.4 Eli Lilly
14.3.5 F.Hoffmann-La Roche
14.3.6 Amylin Pharmaceuticals
14.3.7 Novo-Nordisk
14.3.8 Amgen
14.3.9 Ipsen